Development and application of 'phosphoflow' as a tool for immunomonitoring

Expert Review of Vaccines

Volumn 9, Issue 6, 2010, Pages 631-643

  Wu, Sheng ^a   Jin, Lei ^a   Vence, Luis ^a   Radvanyi, Laszlo G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Flow cytometry; Immunomonitoring; Lymphocyte; Phosflow; Phosphoflow; Phosphorylation; Signaling

Indexed keywords

ALPHA INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; TOLL LIKE RECEPTOR AGONIST; VACCINE;

BIOTECHNOLOGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TYPE; CELLULAR IMMUNITY; DRUG DESIGN; DRUG MEGADOSE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL MONITORING; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PHOSPHOFLOW TECHNOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SCREENING TEST;

ANIMALS; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77953268867     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.59     Document Type: Review

References (71)

1. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 305(5681), 200-205 (2004).
2. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10(1), 11-23 (2009).
3. Britten CM, Gouttefangeas C, Welters MJ et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol. Immunother. 57(3), 289-302 (2008).
4. Walker EB, Disis ML. Monitoring immune responses in cancer patients receiving tumor vaccines. Int. Rev. Immunol. 22(3-4), 283-319 (2003).
5. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294(1-2), 15-22 (2004). (Pubitemid 39626587)
6. Devevre E, Romero P, Mahnke YD. LiveCount assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8+ T-cells by flow cytometry. J. Immunol. Methods 311(1-2), 31-46 (2006).
7. He L, Hakimi J, Salha D, Miron I, Dunn P, Radvanyi L. A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in targeT cells. J. Immunol. Methods 304(1-2), 43-59 (2005).
8. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Ann. Rev. Immunol. 27, 591-619 (2009).
9. Kurosaki T, Shinohara H, Baba Y. B cell signaling and fate decision. Ann. Rev. Immunol. 28, 21-55 (2010).
10. Irish JM, Czerwinski DK, Nolan GP, Levy R. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J. Immunol. 177(3), 1581-1589 (2006).
11. Krutzik PO, Irish JM, Nolan GP, Perez OD. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin. Immunol. 110(3), 206-221 (2004).
12. Perez OD, Nolan GP. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat. Biotechnol. 20(2), 155-162 (2002).
13. Kornblau SM, Tibes R, Qiu YH et al. Functional proteomic profiling of AML predicts response and survival. Blood 113(1), 154-164 (2009).
14. Tsavachidou-Fenner D, Tannir N, Tamboli P et al. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann. Oncol. DOI: 10.1093/ annonc/mdp600 (2010) (Epub ahead of print).
15. Marodi L, Goda K, Palicz A, Szabo G. Cytokine receptor signalling in neonatal macrophages: defective STAT-1 phosphorylation in response to stimulation with IFN-g. Clin. Exp. Immunol. 126(3), 456-460 (2001).
16. Fleisher TA, Dorman SE, Anderson JA, Vail M, Brown MR, Holland SM. Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin. Immunol. 90(3), 425-430 (1999).
17. Uzel G, Frucht DM, Fleisher TA, Holland SM. Detection of intracellular phosphorylated STAT-4 by flow cytometry. Clin. Immunol. 100(3), 270-276 (2001).
18. Tazzari PL, Cappellini A, Bortul R et al. Flow cytometric detection of total and serine 473 phosphorylated Akt. J. Cell. Biochem. 86(4), 704-715 (2002).
19. Perez OD, Kinoshita S, Hitoshi Y et al. Activation of the PKB/AKT pathway by ICAM-2. Immunity 16(1), 51-65 (2002).
20. Chow S, Patel H, Hedley DW. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry 46(2), 72-78 (2001).
21. Zell T, Khoruts A, Ingulli E, Bonnevier JL, Mueller DL, Jenkins MK. Single-cell analysis of signal transduction in CD4 T cells stimulated by antigen in vivo. Proc. Natl Acad. Sci. Am. 98(19), 10805-10810 (2001).
22. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55(2), 61-70 (2003).
23. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298(5600), 1911-1912 (2002).
24. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 296(5573), 1653-1655 (2002).
25. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285(1-2), 1-24 (2002).
26. Lamvik J, Hella H, Liabakk NB, Halaas O. Nonlabeled secondary antibodies augment/ maintain the binding of primary, specific antibodies to cell membrane antigens. Cytometry 45(3), 187-193 (2001).
27. Ebo DG, Dombrecht EJ, Bridts CH, Aerts NE, de Clerck LS, Stevens WJ. Combined analysis of intracellular signalling and immunophenotype of human peripheral blood basophils by flow cytometry: a proof of concept. Clin. Exp. Allergy 37(11), 1668-1675 (2007).
28. Montag DT, Lotze MT. Successful simultaneous measurement of cell membrane and cytokine induced phosphorylation pathways [CIPP] in human peripheral blood mononuclear cells. J. Immunol. Methods 313(1-2), 48-60 (2006).
29. Krutzik PO, Clutter MR, Nolan GP. Coordinate analysis of murine immune cell surface markers and intracellular phosphoproteins by flow cytometry. J. Immunol. 175(4), 2357-2365 (2005).
30. Perez OD, Mitchell D, Campos R, Gao GJ, Li L, Nolan GP. Multiparameter analysis of intracellular phosphoepitopes in immunophenotyped cell populations by flow cytometry. Curr. Protoc. Cytom. 6(6), 20 (2005).
31. Schulz KR, Danna EA, Krutzik PO, Nolan GP. Single-cell phospho-protein analysis by flow cytometry. Curr. Protoc. Immunol. 8(8), 17 (2007).
32. Perez OD, Krutzik PO, Nolan GP. Flow cytometric analysis of kinase signaling cascades. Methods Mol. Biol. 263, 67-94 (2004).
33. Firaguay G, Nunes JA. Analysis of signaling events by dynamic phosphoflow cytometry. Sci. Signal. 2(86), pl3 (2009).
34. Perez OD, Mitchell D, Jager GC et al. Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1. Nat. Immunol. 4(11), 1083-1092 (2003).
35. Krutzik PO, Hale MB, Nolan GP. Characterization of the murine immunological signaling network with phosphospecific flow cytometry. J. Immunol. 175(4), 2366-2373 (2005).
36. Kostianovsky AM, Maier LM, Baecher-Allan C, Anderson AC, Anderson DE. Up-regulation of gene related to anergy in lymphocytes is associated with Notch-mediated human T cell suppression. J. Immunol. 178(10), 6158-6163 (2007).
37. Aerts NE, Dombrecht EJ, Bridts CH et al. Simultaneous flow cytometric detection of basophil activation marker CD63 and intracellular phosphorylated p38 mitogen-activated protein kinase in birch pollen allergy. Cytometry B Clin. Cytom. 76B(1), 8-17 (2008).
38. Irish JM, Kotecha N, Nolan GP. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat. Rev. Cancer 6(2), 146-155 (2006).
39. Irish JM, Anensen N, Hovland R et al. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood 109(6), 2589-2596 (2007).
40. Irish JM, Hovland R, Krutzik PO et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118(2), 217-228 (2004).
41. Van Meter ME, Diaz-Flores E, Archard JA et al. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/ progenitor cells. Blood 109(9), 3945-3952 (2007).
42. Kotecha N, Flores NJ, Irish JM et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14(4), 335-343 (2008).
43. Lee AW, Sharp ER, O'Mahony A et al. Single-cell, phosphoepitope-specific analysis demonstrates cell type- and pathway-specific dysregulation of Jak/ STAT and MAPK signaling associated with in vivo human immunodeficiency virus type 1 infection. J. Virol. 82(7), 3702-3712 (2008).
44. Hotson AN, Hardy JW, Hale MB, Contag CH, Nolan GP. The T cell STAT signaling network is reprogrammed within hours of bacteremia via secondary signals. J. Immunol. 182(12), 7558-7568 (2009).
45. Franceschini D, Paroli M, Francavilla V et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest. 119(3), 551-564 (2009).
46. Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE. Astrocytic regulation of human monocytic/ microglial activation. J. Immunol. 181(8), 5425-5432 (2008).
47. Stitz J, Krutzik PO, Nolan GP. Screening of retroviral cDNA libraries for factors involved in protein phosphorylation in signaling cascades. Nucleic Acids Res. 33(4), e39 (2005).
48. Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat. Methods 3(5), 361-368 (2006).
49. Krutzik PO, Crane JM, Clutter MR, Nolan GP. High-content single-cell drug screening with phosphospecific flow cytometry. Nat. Chem. Biol. 4(2), 132-142 (2008).
50. Lu SX, Alpdogan O, Lin J et al. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. Blood 112(13), 5254-5258 (2008).
51. Dahl ME, Berson A, Lora J, Fuentes M. A novel CCR5-specific pharmacodynamic assay in whole blood using phosphoflow cytometry highlights different ligand-dependent responses but similar properties of antagonists in CD8+ and CD4+ T lymphocytes. J. Pharmacol. Exp. Ther. 327(3), 926-933 (2008).
52. Shachaf CM, Perez OD, Youssef S et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 110(7), 2674-2684 (2007).
53. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100(14), 8372-8377 (2003).
54. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 250(6), 462-475 (2001).
55. Temesgen Z. Interleukin-2 for the treatment of human immunodeficiency virus infection. Drugs Today (Barc.) 42(12), 791-801 (2006).
56. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105-2116 (1999).
57. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 13(Suppl. 4), 16-25 (2008).
58. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28(6), 1075-1083 (2010).
59. Smalley KS. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J. Invest. Dermatol. 130(1), 28-37 (2010).
60. Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14(20), 6674-6682 (2008).
61. Zhao W, Gu YH, Song R, Qu BQ, Xu Q. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 22(6), 1226-1233 (2008).
62. Varker KA, Kondadasula SV, Go MR et al. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin. Cancer Res. 12(19), 5850-5858 (2006).
63. Mortarini R, Vegetti C, Molla A et al. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin. Cancer Res. 15(12), 4085-4094 (2009).
64. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 4(5), e176 (2007).
65. O'Gorman WE, Dooms H, Thorne SH et al. The initial phase of an immune response functions to activate regulatory T cells. J. Immunol. 183(1), 332-339 (2009).
66. Janetzki S, Britten CM, Kalos M et al. 'MIATA' - minimal information about T cell assays. Immunity 31(4), 527-528 (2009).
67. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP. Causal protein-signaling networks derived from multiparameter single-cell data. Science 308(5721), 523-529 (2005).
68. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J. Immunol. Methods 125(1-2), 279-285 (1989).
69. Chao J, DeBiasio R, Zhu Z, Giuliano KA, Schmidt BF. Immunofluorescence signal amplification by the enzyme-catalyzed deposition of a fluorescent reporter substrate (CARD). Cytometry 23(1), 48-53 (1996).
70. Bandura DR, Baranov VI, Ornatsky OI et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal. Chem. 81(16), 6813-6822 (2009).
71. Davis MM. A prescription for human immunology. Immunity 29(6), 835-838 (2008).